エピソード

  • The Pediatrician Who Hid Horrific Abuse Behind Carnival Rides

    The Pediatrician Who Hid Horrific Abuse Behind Carnival Rides
    2026/07/26
    The Pediatrician Who Hid Horrific Abuse Behind Carnival Rides

    Trust and terror sat side-by-side in a waiting room that smelled of cotton candy and motor oil, where Volkswagen Beetle rides and a Buzz Lightyear statue masked a predator trusted by a coastal community. More than thirteen hours of hidden camera footage would later be described by a Harvard pediatric expert as the worst case of physician abuse he'd seen - so how did warnings over fifteen years fail to stop him?

    In this episode, we tell how a pediatrician built a comforting, theatrical practice while multiple sealed complaints, family reports, and peer concerns accumulated for years, and how one recorded tape finally changed everything. What did the footage show that decades of reports and failed warrants could not?

    Person: Earl Brian Bradley
    Location: Lewes, Delaware
    Practice: BayBees Pediatrics
    Patients served: estimated 7,000
    Footage recorded: more than 13 hours

    - Bradley was born May 10, 1953, in Philadelphia, Pennsylvania.
    - He earned his medical degree from Temple University School of Medicine in 1983.
    - Two sealed complaints were filed against him in 1994 and 1995 before he moved to Lewes.
    - In 2004 his sister, Lynda Barnes, reported complaints including inappropriate touching and alleged abuse of his son.
    - In 2005 a warrant request based on peer reports was denied by the attorney general's office for insufficient evidence.

    To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

    © 2026 OBOMEDIA. All rights reserved.
    This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.
    続きを読む 一部表示
    28 分
  • The Carnival Doctor: How Seven Thousand Parents Were Betrayed

    The Carnival Doctor: How Seven Thousand Parents Were Betrayed
    2026/07/25
    The Carnival Doctor: How Seven Thousand Parents Were Betrayed

    A pediatrician whose office featured a Buzz Lightyear statue, a Volkswagen painted like a bumblebee, and a small theatre recorded more than thirteen hours of abuse-yet he kept seeing an estimated seven thousand children before being stopped. How could complaints from his sister, nurses, and other physicians all fail to halt him?

    In this episode, we tell the story of Earl Brian Bradley and the sequence of warnings, reports, and official decisions that allowed his practice to continue in Lewes, Delaware. What went wrong across hospitals, police, and medical review boards that let him keep his appointment book open?

    Person: Earl Brian Bradley
    Date of birth: May 10, 1953
    Education: Temple University School of Medicine (MD, 1983)
    Residency: Pediatrics at Thomas Jefferson University Hospital (completed 1986)
    Practice location: BayBees Pediatrics, Lewes, Delaware

    - More than thirteen hours of videotaped abuse were recorded inside Bradley’s pediatric office.
    - Bradley was estimated to have a patient base of approximately seven thousand children in Lewes.
    - Two complaints were filed against him at Thomas Jefferson University Hospital in 1994 and 1995; both remained unverified and records were sealed.
    - In 2004 Bradley’s sister, Lynda Barnes, reported allegations including inappropriate touching, stolen antidepressants, and abuse of his son to the Delaware state medical society.
    - In 2005 a nurse reported Bradley had been videotaping children; police sought an arrest warrant but the state attorney general’s office found insufficient evidence for prosecution.

    To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

    © 2026 OBOMEDIA. All rights reserved.
    This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.
    続きを読む 一部表示
    27 分
  • ,000 Dead, 17,000 Lawsuits: Who Pays for Hospital Deaths?

    ,000 Dead, 17,000 Lawsuits: Who Pays for Hospital Deaths?
    2026/07/24
    ,000 Dead, 17,000 Lawsuits: Who Pays for Hospital Deaths?

    Every year an estimated 400,000 people die in American hospitals from causes those hospitals introduced or failed to prevent - including 75,000 who die from infections acquired on supposedly clean wards. Why do roughly 17,000 malpractice lawsuits follow a crisis that numbers in the hundreds of thousands, and who, if anyone, is held accountable?

    In this episode, we lay out the numbers and studies behind preventable hospital deaths, legal claims, and the economic flows that follow, showing how patient harm and malpractice compensation move on different tracks. Can the math of deaths, claims, and payouts explain why so few families receive justice?

    Person: John T. James, PhD
    Date: 1984 (first major estimate) and updated studies through 2011
    Event: Landmark reform and largest study of 3.8 million records
    Topic: Preventable hospital deaths, malpractice claims, and compensation flows
    Country: United States

    - 400,000 unnecessary hospital deaths per year attributed to hospital-introduced or unprevented causes, per John T. James.
    - 75,000 deaths per year from hospital-acquired infections, according to CDC figures.
    - ~17,000 malpractice lawsuits filed in the same year when 400,000 deaths were estimated.
    - 1.14 million patient safety incidents identified in 37 million Medicare hospitalizations from 2000-2002.
    - 54% of malpractice payouts went to administrative costs, leaving 46% to patients or families, per a 2006 study.

    To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

    © 2026 OBOMEDIA. All rights reserved.
    This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.
    続きを読む 一部表示
    21 分
  • ,000 Silent Deaths: Why Hospitals Hide the True Toll

    ,000 Silent Deaths: Why Hospitals Hide the True Toll
    2026/07/23
    ,000 Silent Deaths: Why Hospitals Hide the True Toll

    Four hundred thousand Americans die in hospitals each year from preventable harms-more than the CDC’s seventy-five thousand annual deaths from hospital-acquired infections-and only seventeen thousand malpractice cases proceed through the legal system; how does a system that produces that scale of harm also make most of it disappear from public redress? What forces turned these deaths into a statistical abstraction instead of named victims?

    In this episode, we trace the research and records that produced rising estimates of hospital-caused deaths from 1984 onward, follow John T. James’s peer-reviewed tally of four hundred thousand preventable deaths, and unpack why the legal process resolves only a fraction of cases-raising the question of how structural features of medicine and law enable this gap.

    Person: John T. James, PhD
    Date: 1984 (first serious estimate) and 2013 (BMJ Open diagnostic-failure study)
    Topic: Preventable deaths and patient-safety incidents in U.S. hospitals
    Event: 2000-2002 study finding 1.14 million patient-safety incidents across 37 million Medicare hospitalizations
    Case: 2006 closed-claims analysis of 1,452 claims

    - 400,000 preventable hospital deaths per year measured in John T. James’s peer-reviewed study.
    - 44,000-98,000 annual deaths estimated in the 1984 first serious attempt to count hospital-caused deaths.
    - 75,000 annual deaths from hospital-acquired infections reported by the CDC.
    - 1.14 million patient-safety incidents found across 37 million Medicare hospitalizations (2000-2002 study).
    - 17,000 malpractice cases processed per year in the American legal system.

    To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

    © 2026 OBOMEDIA. All rights reserved.
    This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.
    続きを読む 一部表示
    23 分
  • When a Lab Vanished: The Simufilam Data That Disappeared

    When a Lab Vanished: The Simufilam Data That Disappeared
    2026/07/22
    When a Lab Vanished: The Simufilam Data That Disappeared

    Hope turned into doubt when a western blot printout showed identical background pixels across distinct wells - a kind of precision biology never makes - and the missing original data that could have explained it vanished. This episode unravels how a single lab's images helped secure $16 million in federal support and enroll 400 patients in a Phase III trial, and asks: what happens when the evidence that built a drug disappears?

    In this episode, we trace the story of simufilam from early papers and NIH funding to conflicting biomarker results and federal investigations, following the questions left by images, labs, and late-night doors closing. What did the missing source data mean for a drug that promised to reset the protein FLNA and slow Alzheimer's?

    Person: Hoau‑Yan Wang
    Person: Lindsay Burns
    Company: Cassava Sciences
    Grant: more than $16,000,000
    Trial enrollment: 400 patients

    - A western blot printout showed identical background pixel regions where biological noise should have differed.
    - The Journal of Neuroscience published a 2012 paper on the proposed mechanism involving filamin A (FLNA).
    - Neurobiology of Aging published a 2017 paper reporting benefit in an Alzheimer's mouse model.
    - The National Institutes of Health awarded a grant in 2018 that became part of over $16 million in federal support.
    - In May 2020 a biomarker analysis indicated the drug was not working, and in September 2020 Cassava announced an outside lab found improvements.

    To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

    © 2026 OBOMEDIA. All rights reserved.
    This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.
    続きを読む 一部表示
    30 分
  • The Drug That Looked Real: Simufilam's Pixel-Proofed Promise

    The Drug That Looked Real: Simufilam's Pixel-Proofed Promise
    2026/07/21
    The Drug That Looked Real: Simufilam's Pixel-Proofed Promise

    Hope and doubt collided over a pattern of repeating pixels in a lab image, triggering retractions, sixteen million dollars in federal funding, and trials that enrolled hundreds of Alzheimer's patients - but what did those repeating pixels really mean for the people who took the drug? Which part of simufilam’s story was science, and which was something else?

    In this episode, we trace the sequence of events that connected lab images, biomarker shifts, and clinical trials: how FLNA-based theory led to PTI-125 (renamed simufilam), why key experiments all came from a single research group, and how May 2020 biomarker failures were later reported as improvements - but by the same laboratory. What does that chain of evidence reveal about the drug and the trials?

    Person: Hoau-Yan Wang
    Company: Cassava Sciences
    Drug: PTI-125 / simufilam
    Funding: $16,000,000 federal
    Date of confirmation: November 25, 2024

    - Two scientific papers were retracted because the background pixels in western blot images looked too similar.
    - Simufilam produced no clinical benefit and the program was discontinued as confirmed by Cassava Sciences on November 25, 2024.
    - Sixteen million dollars in federal funding supported early clinical trials beginning after NIH funding in 2018.
    - Biomarker results in May 2020 reported failure, then were reported as improved by September 2020, with the later results originating from the same laboratory.
    - All key papers linking FLNA dysregulation and simufilam’s mechanism traced back to Hoau-Yan Wang's lab with no independent replication.

    To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

    © 2026 OBOMEDIA. All rights reserved.
    This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.
    続きを読む 一部表示
    24 分
  • lab printout with repeated pixels became the thread

    lab printout with repeated pixels became the thread
    2026/07/21
    lab printout with repeated pixels became the thread

    The discovery that two western blot images were pixel-for-pixel identical - not similar, identical - triggered an unraveling that touched $16,000,000 in federal grants and sent hundreds of Alzheimer's patients into clinical trials. How could a microscopic flaw in image backgrounds help propel a drug to human trials, and what exactly remains unknown about the science behind it?

    In this episode, we tell the sequence of events that followed that matched background pixels: the history of the academic collaboration, the drug candidate simufilam, the federal funding and clinical trials, and the unresolved questions left by conflicting expert opinions. How did a single laboratory's findings become the foundation for a treatment that showed no biomarker benefit in a phase IIb study?

    Person: Hoau-Yan Wang
    Person: Lindsay Burns
    Company: Pain Therapeutics (later Cassava Sciences)
    Compound: PTI-125 (simufilam)
    Finding: phase IIb biomarker results failed two months after first patient dosing in March 2020

    - The identical western blot pixels were detected in images that were supposed to represent different experiments on different days.
    - $16,000,000 in federal grants were implicated as unraveling after the image discovery.
    - Hundreds of Alzheimer's patients were enrolled in clinical trials of simufilam following the published research.
    - All evidence supporting the filamin A - amyloid beta 42 mechanism came from Wang's laboratory at CUNY, with no independent replication reported.
    - The phase IIb biomarker study reported results that did not show the expected biological improvement two months after dosing began in March 2020.

    To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

    © 2026 OBOMEDIA. All rights reserved.
    This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.
    続きを読む 一部表示
    21 分
  • The Quipazine Puzzle: Tiny Dose, Giant Psychedelic Question

    The Quipazine Puzzle: Tiny Dose, Giant Psychedelic Question
    2026/07/21
    The Quipazine Puzzle: Tiny Dose, Giant Psychedelic Question

    A single bracketed word - "[sic]" - appeared next to a reported dose of 0.5 mg, implying someone claimed a mescaline-like effect from less than a grain of salt. Quipazine has been studied since 1966, produced LSD-like substitution in animals, and provoked projectile vomiting in primates; so what exactly does it do in the human brain?

    In this episode, we trace quipazine’s scientific trail from 1966 through rodent and primate studies, the shifting labels from antidepressant to psychedelic candidate, and the locked doctoral thesis that may hold part of the answer - can one molecule explain both psychedelic and emetic effects at similar doses?

    Person: researchers (unnamed) who reported 0.5 mg dose marked "[sic]"
    Date: 1966 (first appearance in literature)
    Event: 1977 animal studies documenting psychedelic-like behaviors
    Topic: serotonin 2-A receptor activation (head-twitch response, ketanserin blockade)
    Status: doctoral thesis under embargo until 2030

    - Reported dose printed next to the notation "[sic]": 0.5 mg
    - First appearance of quipazine in scientific literature: 1966
    - By 1971 quipazine described as an antidepressant-like agent
    - 1977 animal studies showed head-twitch response indicative of serotonin 2-A activation
    - Primate studies produced LSD-like behaviors plus projectile vomiting, linking psychedelic and emetic effects

    To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

    © 2026 OBOMEDIA. All rights reserved.
    This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.
    続きを読む 一部表示
    32 分